06-24-2020: Zynex, Inc. (ZYXI): Pain Management

(WAIT FOR PAGE TO LOAD COMPLETELY BEFORE LINKS WORK.)

Corporate Webpages
Company Profile
Company History
News
Comparison with Peers
Bond Issue
Zenith Index
Financial Statements
Avg. P/E to Current P/E
Financial Ratios
Intrinsic Value (Disc. CashFlow)
Fair Value Estimator
Projected Earnings
Research Reports
Analysts' Opinions
Insider Activity
Institutional Activity
Sentiment
Short Interest
Standard & Poor's
Management's Discussion
Channel Potential
MACD Histogram
Intraday Chart
Val Idea
Stock Consultant
Point & Figure Chart
Wall Street Analyzer
Marketspace Chart
Time Series Forecast
Neural Network Prediction
Stock Options
Ultimate Trading Systems
Recommendation

Zynex, Inc.

Many in America's aging population suffer from aches and pains due to arthritis, sciatica, back pains, muscle strain, etc. Zynex, Inc. (ZYXI) is a maker of medical devices to ease pain, especially through electronic stimulation, such as one would find in a transcutaneous electrical nerve stimulation unit (TENS device). Sales of their medical devices have been growing rapidly.

ZYXI started out as a penny stock in the over-the-counter bulletin board market, where only a few stocks ever make it from their to the NASDAQ. As recently as 2016, this stock would have been in danger of being delisted in on the NASDAQ because of low share price. But in 2019, the stock began trading on the NASDAQ with previous history from the OTCBB market. It operates in three major divisions, devices for pain management, cardiac monitoring, and devices for neurological diagnosis.

The company is in a very competitive medical device industry with at least 84 competitors according to one source. The industry group is recently strong and ZYXI stock is among the strongest in that group. Analysts are generally favorable, but researchers entirely divided in their opinions. Institutions are net acquirers.

The company has a very strong Zenith Index indicating good fundamentals and growth prospects, although the p/e is high due to a recent extraordinary share price runnup in an upside breakout pattern still going on. News is generally good maintaining earnings beating Wall Street expectations for the most part. The company does considerable business in China although based in Colorado.

The stock chart recently looks weak and a bit toppy. The parabolic stop and reverse (SAR) system developed by Welles Wilder appear to have worked extremely well on this particular stock with many in-and-out trades recently, with the stock moving just enough after gaining some momentum to maintain that momentum long enough to validate signals.



[Home]
Corporate Wepages

Trade Mark
01
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24



[Home]
Company Profile

Profile



[Home]
Company History
6 7


[Home]
News

Click Here for News Archives



[Home]
Comparison

Comparison

Groups 1
Groups 2
Groups 3


Companies 1
Companies 2
Companies 2
Companies 2

Similar Companies Performance:

55 56
57 58
59 60


[Home]
Bond Issue

22



[Home]
Zenith Index

Under current market conditions, a Zenith Index Score of 1.20 or above is required for a positive rating on this factor. 1.21 -1.30 is considered acceptable, 1.30-1.40 is considered strong and
> 1.40 is considered exceptionally strong. Accounting statements in this section often contain mistakes, especially in earlier years' totals, but data is deemed sufficient for us to give a rating. More accurate financial statements follow in the next section.

ZYXI  Zynex Inc.
   Exchange: NASD                   Group: Medical
                                    Industry: Medical Products
   Rank of Industry:  37            Rank within Industry: 93 out of 2

      Shares Out:   33.19 (mil.)   Market Capitalization:$    799.00 (mil.)
      Sales (12 mo.): $     45.00 (mil.)              Sales Growth:  65.59%
      Avg Broker Recommend (1=Strong Buy): 2.00   Consensus Target:  22.41
      Dividend:$ 0.00  Yield: 0.00%  Payout Ratio: 0.00  Payout Chg:  0.00%

      Zynex, Inc. engineers, manufactures, markets, and sells medical devices
      for the electrotherapy, and stroke and spinal cord injury rehabilitation
      markets primarily in the United States. The company primarily offers
      electrotherapy products for pain relief and pain management; and
      NeuroMove for stroke and spinal cord injury rehabilitation. The
      company's product lines are fully developed, FDA-cleared, commercially
      sold, and have been developed to uphold the Company's mission of
      improving the quality of life for patients suffering from impaired
      mobility due to stroke, spinal cord injury, or debilitating and chronic
      pain. Zynex markets its products through commissioned and independent
      sales representatives, as well as directly to end users through
      advertisements and articles in relevant publications.

   Recent Price: 413.00     52-Week High:  27.00     52-Week Low:   7.12

   20-Day Avg. Daily Volume =  1,357,625                    Beta:   1.12

Earnings per Share (EPS) Estimates:

                        This        Next        This        Next
                       Quarter     Quarter      Year        Year
                      06/2020     09/2020     12/2020     12/2021

    Average Estimate      0.00        0.85        0.00        0.00
 Number of Estimates         3           3           4           4
        Low Estimate      0.06        0.08        0.37        0.55
       High Estimate      0.08        0.11        0.47        0.97
        Year Ago EPS      0.06        0.06        0.28        0.40
          EPS Growth     16.67%      50.00%      42.86%      95.00%

P/E Ratio Related Data:                                    EPS       Sales
  Current FY Estimate:  80.20                              Growth    Growth
   Trailing 12 Months:  59.78       vs. Previous Quarter:    0.00%     7.53%
     P/E Growth Ratio:   0.00          vs. Previous Year:   28.57%    65.59%

Price/Sales Ratio: 15.51    Price/Book Ratio: 34.26    Price/Cash Flow: 76.71

Other Fundamental Data:
                         03/31/20     12/31/19      09/30/19
Return on Investment         0.00        61.51         71.39
Return on Assets            37.31        40.52         43.31
Current Ratio                4.40         4.34          0.12
Quick Ratio                  3.82         3.88          0.65
Operating Margin            19.57        20.87          2.56
Net Margin                  19.57        20.87          2.56
Pre-Tax Margin               0.00         0.00          0.00
Book Value                   0.60         0.28          0.15
Inventory Turnover           4.51         5.18          0.96
Debt-to-Equity Ratio         0.18         0.17          0.23
Debt-to-Capital Ratio       14.90        14.85          8.87

Reported and Estimated Quarterly Earnings:
Reported                                03/2020   12/2019   09/2019   06/2019
                                           0.09      0.09      0.06      0.06
Estimated                              06/2020   09/2020   12/2020   12/2021
  Consensus 7 Days Ago                     0.07      0.09      0.40      0.78
  Upward Revisions                            0         0         0         0
  Downward Revisions                          0         0         0         0
  Consensus 30 Days Ago                    0.07      0.09      0.40      0.74
  Upward Revisions                            0         0         1         1
  Downward Revisions                          0         0         0         0


Annual Income Statements ($mil except EPS data):

                                   12/31/19 12/31/18 12/31/17 12/31/16 12/31/15

Sales                                 45.00    32.00    23.00    13.00    12.00
Cost of Goods                          9.00     6.00     5.00     4.00     5.00
Gross Profit                          37.00    26.00    19.00    10.00     7.00
Selling, Deprec, Amort Expense        26.00    16.00    10.00     9.00     9.00
Income After Deprec + Amortization    11.00    10.00     9.00     1.00    -2.00
Non-Operating Income                   1.00     0.00     0.00     0.00     0.00
Interest Expense                       0.00     0.00     1.00     0.00     1.00
Pretax Income                         12.00    10.00     7.00     0.00    -3.00
Income Taxes                           2.00     1.00     0.00     0.00     0.00
Minority Interest                      0.00     0.00     0.00     0.00     0.00
Investment Gains/Losses                0.00     0.00     0.00     0.00     0.00
Other Income/Charges                   0.00     0.00     0.00     0.00     0.00
Income from Continuing Operations      9.00    10.00     7.00     0.00    -3.00
Extras + Discontined Operations        0.00     0.00     0.00     0.00     0.00
Net Income                             0.00    10.00     7.00     0.00    -3.00
Income before Depr. + Amortization    12.00    11.00    10.00     1.00    -2.00
Depreciation + Amort. (Cash Flow)      0.00     0.00     0.00     0.00     0.00
Average Shares                        33.96    34.04    33.20    31.27    31.27
Diluted EPS bf Non-Recurring Items     0.28     0.28     0.22     0.00    -0.09
Diluted Net EPS                        0.28     0.28     0.22     0.00    -0.09


Balance Sheets ($mil. except per share data):

                                   12/31/19 12/31/18 12/31/17 12/31/16 12/31/15
Assets:

Cash + Equivalents                     0.00    14.00    10.00     6.00     0.00
Receivables                            6.00     3.00     2.00     3.00     2.00
Notes Receivable                       0.00     0.00     0.00     0.00     0.00
Inventories                            2.00     1.00     0.00     0.00     0.00
Other Current Assets                   0.00     1.00     0.00     0.00     0.00
Total Current Assets                  23.00    14.00     8.00     3.00     3.00
Property, Plant & Equipment            1.00     1.00     0.00     1.00     1.00
Investments + Advances                 0.00     0.00     0.00     0.00     0.00
Other Non-Current Assets               0.00     0.00     0.00     0.00     0.00
Deferred Charges                       1.00     1.00     0.00     0.00     0.00
Intangibles                            0.00     0.00     0.00     0.00     0.00
Deposits + Other Assets                4.00     0.00     0.00     0.00     0.00
Total Assets                           0.00    28.00    16.00     9.00     4.00

                                   12/31/19 12/31/18 12/31/17 12/31/16 12/31/15
Liabilities:

Notes Payable                          0.00     0.00     0.00     0.00     0.00
Accounts Payable                       2.00     2.00     2.00     3.00     2.00
Current Portion Long-Term Debt         1.00     0.00     0.00     3.00     4.00
Current Portion Capital Leases         0.00     0.00     0.00     0.00     0.00
Accrued Expenses                       2.00     1.00     1.00     1.00     1.00
Income Taxes Payable                   0.00     1.00     0.00     0.00     0.00
Other Current Liabilities              0.00     3.00     1.00     1.00     0.00
Total Current Liabilities              5.00     6.00     4.00     8.00     8.00
Mortgages                              0.00     0.00     0.00     0.00     0.00
Deferred Income Taxes                  0.00     1.00     0.00     0.00     0.00
Convertible Debt                       0.00     0.00     0.00     0.00     0.00
Long-Term Debt                         3.00     0.00     0.00     0.00     0.00
Non-Current Capital Leases             0.00     0.00     0.00     0.00     0.00
Other Non-Current Liabilities          0.00     0.00     0.00     0.00     0.00
Minority Interest                      0.00     0.00     0.00     0.00     0.00
Total Liabilities                      0.00     9.00     7.00     4.00     8.00

                                   12/31/19 12/31/18 12/31/17 12/31/16 12/31/15
Shareholder Equity:

Preferred Stock                        0.00     0.00     0.00     0.00     0.00
Common Sock                            0.00     0.00     0.00     0.00     0.00
Capital Surplus                        9.00     8.00     8.00     6.00     6.00
Retained Earnings                     14.00     5.00    -2.00   -10.00   -10.00
Other Equity                           0.00     0.00     0.00     0.00     0.00
Treasury Stock                         4.00     4.00     0.00     0.00     0.00
Total Shareholder Equity              20.00     9.00     5.00    -4.00    -4.00
Total Liabilities+ Owners' Equity     28.00    16.00     9.00     4.00     4.00
Total Common Equity                    0.00     0.00     0.00     0.00     0.00
Shares Outstanding                    32.70    33.20    32.80    31.20    31.20
Book Value per Share                   0.60     0.28     0.15    -0.12    -0.13


Cash Flow Statement:

    Operations, Investments, & Financial Activities

                                   12/31/19 12/31/18 12/31/17 12/31/16 12/31/15

Net Income                             0.00     9.49     9.55     7.37     0.07
Depreciation/Amortization + Deplet     0.78     0.60     0.80     0.44     0.42
Net Change in Assets/Liab.            -4.30    -0.39    -1.16    -0.42     1.65
Net Cash f Discontinued Operations     0.00     0.00     0.00     0.00     0.00
Other Operating Activities             0.34    -0.35     1.26     1.69     1.20
Net Cash f Operating Activities        0.00     6.30     9.41     8.26     1.77
Property + Equipment                  -0.16    -1.08    -0.09     0.00     0.01
Acquisition/Disp. of Subsidiaries      0.00     0.00     0.00     0.00     0.00
Investments                            0.00     0.00     0.00     0.00     0.00
Other Investing Activity               0.00     0.00     0.00    -0.23     0.10
Net Cash from Investing               -0.16    -1.08    -0.09    -0.23     0.11

    Use of Funds

                                   12/31/19 12/31/18 12/31/17 12/31/16 12/31/15

Issue (Repurchase) Capital Stock       0.05    -3.26    -0.18     0.00     0.00
Issuance (Repayment) of Debt          -0.02    -0.51     0.25    -0.07    -0.06
Increase/Decrease Short-Term Debt      0.00     0.00    -2.77    -1.23    -0.44
Dividends + Distributions              0.00     0.00     0.00     0.00     0.00
Other Financing Acitivies              0.00     0.00    -0.16     0.00     0.00
Net Cash from Financing               -2.23    -3.76    -2.86    -1.30    -0.50
Effect of Exchange Rate Changes        0.00     0.00     0.00     0.00     0.00

Net Change in Cash + Equivalents       3.91     4.56     5.32     0.24    -0.06

    Net Change in Cash & Equivalents

                                   12/31/19 12/31/18 12/31/17 12/31/16 12/31/15

Cash at Beginning of Per.             10.13     5.57     0.25     0.01     0.06
Cash at End of Period                 14.04    10.13     5.57     0.25     0.01
Net Change in Cash + Equivalents       3.91     4.56     5.32     0.24    -0.06


Zenith Indices:                      [Indices near +3.0, or near zero,
                                     or < zero bear special attention.]
P/E Ratio Tests:
Current P/E Ratio < 28?    0.4684     P/E Ratio > 5?             1.0000
P/E Ratio Vs Growth Rate:  0.7170     Forward P/E Ratio < 28?    0.3491

Sales Tests:
Sales < $500 mil.?         3.0000     Sales incr. 25% Yearly?    2.6236
Sales > $340 million?      0.0941     Inventory/Sales < 5%?      1.6000

Balance Sheet Tests:
Debt/Equity Ratio < 0.40?  2.3529     LTD/Net Assets:            3.0000
Debt Reduction:            3.0000     Intangibles/Assets < 10%?  3.0000
Current Ratio > 2?         3.0000     Return on Equity > 9.8%?   3.0000

Earnings Tests:
EPS 5-Yr. Growth > 18%?    3.0000     Operating Margin > 5%?     0.2396
EPS Annual Growth > 0%?    0.0000     Dividend Rate cp 2.7%:     0.0000
Earnings Consistent?       1.6667     Payout Ratio Decreasing?   1.2000
Net Income Increasing 25%? 1.1429     Price<15% below 52-wk Hi?  3.0000
Positive Cash Flow?        1.8187     Price/Book X PE < 22?      0.0107
Profit Margin > 7.5%?      2.7827     Price/Book < 1.6?          0.0467
Profit Margin Increasing?  3.0000     Stock Compared to S+P 500: 3.0000
Price & Float Tests:
Return on Investment>12%?  3.0000     Shares Out > 50 mil.?      0.6638
Return on Assets > 10%?    3.0000     Beta > 1.25?:              1.1200
Price/Sales Ratio < 2.3?   3.0000     Liquidity > 2%?            3.0000

Ownership Tests:
Analyst Following > 2.0?   1.5000     Market Capital'n > 300M?   2.6633
Owner's Equity Increasing?-2.2500     Shares Out Decreasing?     0.9398

ZYXI                                   Overall Zenith Index:     1.9873


[Home]
Financial Statements

ZYNEX INC  (ZYXI)                           INCOME STATEMENT

Fiscal year ends in December. USD in thousand        2015-12         2016-12         2017-12         2018-12         2019-12             TTM           

Revenue                                               11,641          13,313          23,432          31,917          45,472          51,504
Cost of revenue                                        4,937           3,517           4,819           6,038           8,814          10,431
Gross profit                                           6,704           9,796          18,613          25,879          36,658          41,073


Operating expenses
Sales, General and administrative                      9,185           9,156           9,669          15,509          25,592          29,805
Total operating expenses                               9,185           9,156           9,669          15,509          25,592          29,805

Operating income                                      -2,481             640           8,944          10,370          11,066          11,268
Interest Expense                                         503             352           1,450             154               5               0
Other income (expense)                                    -7            -204               0               0             880              -9
Income before taxes                                   -2,991              84           7,494          10,216          11,941          11,259
Provision for income taxes                               -57              15             129             664           2,449           1,180
Net income from continuing operations                 -2,934              69           7,365           9,552           9,492          10,079
Other                                                     23               0               0               0               0               0
Net income                                            -2,911              69           7,365           9,552           9,492          10,079
Net income available to common shareholders           -2,911              69           7,365           9,552           9,492          10,079

Earnings per share
Basic                                                  -0.09            0.00            0.23            0.29            0.29            0.31 
Diluted                                                -0.09            0.00            0.22            0.28            0.28            0.30 

Weighted average shares outstanding
Basic                                                 31,271          31,271          32,156          32,503          32,439          32,609
Diluted                                               31,271          31,271          33,196          34,043          33,963          34,084

____________________________________________________________________________________________________________________________________________


ZYNEX INC  (ZYXI)                           BALANCE SHEET

Fiscal year ends in December. USD in thousand        2015-12         2016-12         2017-12         2018-12         2019-12             

Assets

Current assets

Cash

Total cash                                                 8             247           5,565          10,128          14,040

Receivables                                            2,426           3,028           2,185           2,791           5,833
Inventories                                              305             107             423             837           2,378
Prepaid expenses                                          27              40             198             570             315
Total current assets                                   2,766           3,422           8,371          14,326          22,566

Non-current assets

Property, plant and equipment
Gross property, plant and equipment                    2,432           2,523           1,202           2,281           6,932
Accumulated Depreciation                              -1,631          -1,943          -1,014          -1,462          -2,063
Net property, plant and equipment                        801             580             188             819           4,869

Intangible assets                                         74              34               0               0               0
Deferred income taxes                                      0               0               0             725             513
Other long-term assets                                    55              55             370             314             329
Total non-current assets                                 930             669             558           1,858           5,711

Total assets                                           3,696           4,091           8,929          16,184          28,277 

Liabilities and stockholders' equity

Liabilities

Current liabilities
Short-term debt                                        4,002           2,771             231               0               0
Capital leases                                           109             118             123               0           1,256
Accounts payable                                       2,477           2,879           2,243           1,552           2,133
Taxes payable                                             79              94               0             688              52
Accrued liabilities                                      783             949             538             908           1,748
Deferred revenues                                         89              54               0               0               0
Other current liabilities                                  0             880             880           3,207               8
Total current liabilities                              7,539           7,745           4,015           6,355           5,197

Non-current liabilities
Capital leases                                           216             136               0               0           3,427
Minority interest                                        -89             -89             -89             -89             -89
Other long-term liabilities                               12              12              12             531               0
Total non-current liabilities                            139              59             -77             442           3,338

Total liabilities                                      7,678           7,804           3,938           6,797           8,535 

Stockholders' equity

Common stock                                              31              31              33              34              34
Additional paid-in capital                             5,832           6,032           7,612           8,157           9,198
Retained earnings                                     -9,845          -9,776          -2,411           4,871          14,356
Treasury stock                                             0               0            -243          -3,675          -3,846
Total stockholders' equity                            -3,982          -3,713           4,991           9,387          19,742
Total liabilities and stockholders' equity             3,696           4,091           8,929          16,184          28,277

____________________________________________________________________________________________________________________________________________


ZYNEX INC  (ZYXI)                           Statement of CASH FLOW

Fiscal year ends in December. USD in thousand        2015-12         2016-12         2017-12         2018-12         2019-12             TTM           

Cash Flows From Operating Activities
Net income                                            -2,934              69           7,365           9,552           9,492          10,079
Depreciation & amortization                              424             435             286             448             778             870
Investment/asset impairment charges                        0              30               0               0               0               0
Deferred income taxes                                      0               0               0            -725             212          -1,047
Stock based compensation                                 130             200              66             370             820           1,177
Change in working capital                              1,653            -420          -1,162            -607          -4,304          -5,149
Accounts receivable                                     -277          -2,018             843            -606          -3,042          -3,403
Inventory                                              1,602             198            -316            -414          -2,360          -3,495
Prepaid expenses                                         223             -14            -473            -372             255            -394
Accounts payable                                         -67             402               0            -515               0               0
Accrued liabilities                                      -20             167               0             370               0               0
Income taxes payable                                       0               0               0             554               0               0
Other working capital                                    192             845          -1,216             376             843           2,143
Other non-cash items                                   1,068           1,455           1,705             370            -695            -759
Net cash provided by operating activities                341           1,769           8,260           9,408           6,303           5,171

Cash Flows From Investing Activities
Investments in property, plant, and equipmen               0               0             -87          -1,082            -160            -411
Property, plant, and equipment reductions                  9               0               0               0               0               0
Other investing activities                                99            -226               0               0               0               0
Net cash used for investing activities                   108            -226             -87          -1,082            -160            -411

Cash Flows From Financing Activities
Debt issued                                                0               0           1,035               0               0               0
Debt repayment                                           -64             -72            -781            -507             -19             -26
Common stock issued                                        0               0              39             176             221             435
Common stock repurchased                                   0               0            -377          -3,432            -171               0
Dividend paid                                              0               0               0               0          -2,262              -3
Other financing activities                              -440          -1,232          -2,771               0               0               0
Net cash provided by (used for) financing               -504          -1,304          -2,855          -3,763          -2,231             406

Net change in cash                                       -55             239           5,318           4,563           3,912           5,166
Cash at beginning of period                               63               8             247           5,565          10,128           9,419
Cash at end of period                                      8             247           5,565          10,128          14,040          14,585

Free Cash Flow
Operating cash flow                                      341           1,769           8,260           9,408           6,303           5,171
Capital expenditure                                        0               0             -87          -1,082            -160            -411
Free cash flow                                           341           1,769           8,173           8,326           6,143           4,760
____________________________________________________________________________________________________________________________________________





[Home]
Average to Current P/E Ratios
              (ZYXI)     Zynex Inc.

                               2015    2016    2017    2018    2019

          Annual Earnings:    -0.09    0.00    0.22    0.28    0.28
Average Price During Year:     0.21    0.30    2.56    3.41    8.42

                P/E Ratio:     2.29    3.02   11.64   12.18   30.08

 Average 5-Year P/E Ratio  =  11.84
             Current Price =  24.34

Previous 5 Quarter Earnings:   0.07    0.06    0.06    0.09    0.09

          Current Annualized (Last Four Quarters) Earnings =   0.24
                                                           ________
                                 Average PE / Current PE =     0.12
                                                           --------

                                      ...a number above 1.00 is good
                                                1.00 or below is bad


[Home]
Financial Ratios

. . . . . . . . . . . . Lowest to Highest, Compared to Industry



[Home]
Intrinsic Value (DCF)

Intrinsic Value by Discounted Cash Flow Method:

Intrinsic Value



[Home]
Fair Value Estimator

Fair Value Estimate:

Fair Value



[Home]
Projected Earnings

Earnings Estimates



[Home]
Research Reports

Click Here for Research Reports



[Home]
Analysts' Opinions

Analysts' Opinion 1
Analysts' Opinion 1
Analysts' Opinion 1
Analysts' Opinion 1
Analysts' Opinion 2



[Home]
Insider Activity

Insiders Chart Insider Trades
Insider Trades
Executive Compensation



[Home]
Institutional Activity

Institutional Ownership:

institutions 1
Mutual Fund Ownership:

institutions 2


[Home]
Sentiment

sentiment

Zenith uses the "sentiment" score above or below 50 to award a positive or negative point in the Decision Matrix.

sentiment sentiment sentiment sentiment



[Home]
Short Interest Ratio

As the short interest rises as a percentage of average daily share volume (Days to Cover), this is considered a measure of negative sentiment. Similarly, a decrease in that percentage is considered positive sentiment.

short interest short interest


[Home]
Standard & Poor's

S&P Stock Report (Requires Adobe Acrobat Reader)



[Home]
Management's Discussion of Results of Operations Excerpts

Click Here for Management's Discussion Excerpts



[Home]
Channeling Potential

 
The summary below includes a value for `Degree,' which refers on a
scale of 1 to 10 the range of a channel in the period under consi-
deration compared to the total range of price movement. It also looks
for the last closing price to be within the channel, otherwise zeroed.
The `Index' is the `Degree' weighted for volatility.  Generally, the
the higher the index, the more suitable is the stock for trading as
a `rolling stock' between channel high and low points.

Results for ZYNEX INC.:
Symbol? ZYXI
Total Months Available: 103
       Months in Cycle?   4

Months Covered by Periods:  12

Period 1           Period 2          Period 3
   H1      L1        H2      L2        H3      L3
  13.10    7.12     11.40    7.51     27.00    7.93

RANGE   =  27.00  TO    7.12            Close =  24.00
CHANNEL =  11.40  TO    7.93           Degree =   2
Volatility =  14.46%                    Index =   2
Channel Chart



[Home]
MACD Histogram Divergence

The theory is that connecting the two most recent peaks or valleys of the MACD histogram will signal the direction of the next major move.



[Home]
Intraday Chart

2 Days:



[Home]
Val Idea

3 out of 8 favorable, (negative opinion.)

Val Idea
Val Idea


[Home]
Stock Consultant

Stock Consultant Stock Consultant


[Home]
Point & Figure Chart

P & F Chart


[Home]
Wall Street Analyzer



[Home]
Marketspace Chart

Marketspace Chart



[Home]
Time Series Forecast

Time Series 1 Time Series 2


[Home]
Neural Network Prediction

"Neurostock" can only track long trades. Therefore its performance, as tracked by itself on stocks which are consistently falling, may not appear as good as it could if each "sell" signal were a "short sale."

Neural Chart
Heading
Neural Trades Neural Prediction



[Home]
Ultimate Trading Systems

2 out of 3 of the ultimate systems favor an upmove.


System Below:
Short term outlook: Positive: Bright Green, Negative: Bright Red
Long term outlook: Postive: Dark Green, Negative: Dark Red.




[Home]
Recommendation

Decision Weighting Factors
FactorsWeighted Points
News + 1
Comparison - 1
Industry + 1
Bond Issue 0
Zenith Index + 1
Non-GAAP vs. GAAP Earnings - 1
Cash Flow + 1
Average to Current P/E - 1
Ratios + 1
Intrinsic Value DCF - 1
Fair Value Estimator - 1
Projected Earnings + 1
Research Reports + 1
Analysts + 1
Executive Perquisites + 1
Insider Activity - 1
Institutional Activity + 1
Management Reporting + 1
Short Interest + 1
Sentiment + 1
Standard & Poor's + 1
MACD Histogram Divergence - 1
Val Idea - 1
Stock Consultant - 1
Point & Figure + 1
Wall Street Analyzer - 1
Marketspace Chart - 1
Time Series Chart - 1
Neural Network + 1
Stock Options + 1
Ultimate Trading Systems + 1
Total + 6
Place 1,230 shares of Zynex, Inc. (ZYXI) on the Active List.